Emerging Nanotechnology Approaches for HIV/AIDS Treatment and Prevention
- 11 February 2010
- journal article
- review article
- Published by Taylor & Francis Ltd in Nanomedicine
- Vol. 5 (2), 269-285
- https://doi.org/10.2217/nnm.10.1
Abstract
Currently, there is no cure and no preventive vaccine for HIV/AIDS. Combination antiretroviral therapy has dramatically improved treatment, but it has to be taken for a lifetime, has major side effects and is ineffective in patients in whom the virus develops resistance. Nanotechnology is an emerging multidisciplinary field that is revolutionizing medicine in the 21st century. It has a vast potential to radically advance the treatment and prevention of HIV/AIDS. In this review, we discuss the challenges with the current treatment of the disease and shed light on the remarkable potential of nanotechnology to provide more effective treatment and prevention for HIV/AIDS by advancing antiretroviral therapy, gene therapy, immunotherapy, vaccinology and microbicides.This publication has 148 references indexed in Scilit:
- A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapyVaccine, 2009
- X-Ray Structures of the Hexameric Building Block of the HIV CapsidCell, 2009
- Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbitsVirology, 2009
- Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissuesAdvanced Drug Delivery Reviews, 2009
- Durable Protection from Herpes Simplex Virus-2 Transmission Following Intravaginal Application of siRNAs Targeting Both a Viral and Host GeneCell Host & Microbe, 2009
- T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized MiceCell, 2008
- Inhibition of HIV Fusion with Multivalent Gold NanoparticlesJournal of the American Chemical Society, 2008
- The structural biology of HIV assemblyCurrent Opinion in Structural Biology, 2008
- Optimizing Size and Copy Number For PEG-fMLF (N-Formyl-methionyl-leucyl-phenylalanine) Nanocarrier Uptake by MacrophagesBioconjugate Chemistry, 2007
- Peritoneal Macrophage Uptake, Pharmacokinetics and Biodistribution of Macrophage-Targeted PEG-fMLF (N-Formyl-Methionyl-Leucyl-Phenylalanine) Nanocarriers for Improving HIV Drug DeliveryPharmaceutical Research, 2007